The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...

Compass Pathways (NASDAQ:CMPS) shares rose nearly 9% premarket on Friday after the biotechnology company priced a securities offering to raise up to $353M. The company is offering ~24.01M American ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Franklin Resources Inc. boosted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS – Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other ...